BioNTech said Thursday that it expects its Covid-19 vaccine, jointly developed with Pfizer, to be available to 12-to-15-year-olds in Europe from June.
The German firm's CEO Ugur Sahin told Der Spiegel weekly that it was "in the final stretches" of preparing its submission for European regulatory approval.
The evaluation of the trial data "takes four to six weeks on average", he added.